Screening of prostate cancer from blood. bioMérieux and ExonHit Therapeutics announce, today, the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer.
News24 March, 2020
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical...
bioMérieux, a major player in the field of in vitro diagnostics, is reinforcing its commitment to combating cardiovascular diseases by launching VIDAS Troponin I Ultra, a first-line parameter in acute coronary syndrome diagnostics.
bioMérieux will be awarded up to €54.5 million by France’s Agence de l’Innovation Industrielle to pursue molecular biology research
bioMérieux today announced that it will be awarded up to €54.5 million over the next ten years by France’s Agence de l’Innovation Industrielle to help fund the “Advanced Diagnostics and New therapeutic Approaches” (ADNA) program, led by Mérieux Alliance. Of this amount, €25.6 million will be in the form of grants and €28.9 million in the form of loans. The financing is subject to approval by the European Union, which is expected to make a decision in the second quarter of 2007.
bioMérieux was proud to present its ninth Award on Pathogen Research at the “Eleventh Conference on Food Microbiology”, held this year by the University of Ghent, Belgium, on September 14th and 15th.
A major player in in vitro diagnostics specialized in the fight against infectious diseases, bioMérieux confirms its success in the fight against the AIDS virus in Africa.
bioMérieux, a global leader in the field of in vitro diagnostics, today announced the closing of the sale of its hemostasis range of products to Trinity Biotech plc.
bioMérieux, the world's third-largest diagnostic company in the field of infectious diseases, has won a new contract ; the company will be the exclusive provider of equipment for measuring HIV viral load in the Democratic Republic of Congo.